Laman UtamaLSTA • NASDAQ
add
Lisata Therapeutics Inc
Tutup sebelumnya
$2.47
Julat hari
$2.31 - $2.53
Julat tahun
$1.87 - $4.20
Permodalan pasaran
21.81J USD
Bilangan Purata
11.54K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Invezz
1 hari lalu
Amaran risiko: ‘kemelesetan sederhana’ boleh menjejaskan tahap S&P 500 kepada 3,700
0.74%
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 1.00J | — |
Perbelanjaan pengendalian | 5.95J | -1.26% |
Pendapatan bersih | -4.61J | 14.07% |
Margin untung bersih | -461.00 | — |
Pendapatan bagi setiap syer | -0.55 | 16.67% |
EBITDA | -4.91J | 17.90% |
Kadar cukai berkesan | 0.00% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 31.24J | -38.17% |
Jumlah aset | 35.00J | -36.00% |
Jumlah liabiliti | 5.68J | -16.40% |
Jumlah ekuiti | 29.32J | — |
Syer tertunggak | 27.70J | — |
Harga kepada buku | 0.70 | — |
Pulangan pada aset | -33.80% | — |
Pulangan pada modal | -39.23% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -4.61J | 14.07% |
Tunai daripada operasi | -4.53J | -11.28% |
Tunai daripada pelaburan | 1.39J | 124.31% |
Tunai daripada pembiayaan | -96.00K | -500.00% |
Perubahan bersih dalam tunai | -3.30J | 66.45% |
Aliran tunai bebas | -2.95J | -25.90% |
Perihal
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Diasaskan
1980
Ibu pejabat
Tapak web
Pekerja
26
